GET YOUR COVID-19 RESULTS ON SAME DAY OR IN 24 HRS
No Out-Of Pocket Costs Thru HSA, FSA, or Insurance claim. Receipts provided for reimbursement. Self-Pay accepted also.
Lab PCR is the gold standard of COVID-19 testing for the highest accuracy.
COVID-19 testing made easy. No lines, no Waits, Just Fast Results! Whether you need COVID-19 testing results for travel, for businesses, or for peace of mind, the Expert Team at
KONE MOLECULAR LABS™ delivers your results on time.
1 to 2 Days
We deliver your results via text, email, or a patient portal.
At KONE MOLECULAR LABS™, we value the importance of accuracy. Our choice of high performance testing equipment are designated to do just that.
Come test with us! Travel Certificate provided on the day of results!
You have options!
ON-DEMAND COVID TESTING
Use one of our drive-thru locations, we can come to you, or we can send you a collection kit of your choice!
Get Tested Today!
Nasal Swab; We'll come to you, or you may visit us at one of our collection/testing sites.
Your sample is processed immediately using the Abbott ID Ag Card to detect COVID-19.
Results within 15 minutes. (Results timeline subject to surge & positivity rates)
This is for the TEST ONLY; No report or Lab Certificate provided.
Test Kit Options
(HSA and FSA; or Self-Pay)
• Saliva Based Kit
• Nasal Swab Kit
√ Step 1: Select your kit of choice to receive it within 24hours in the comfort of your home or office via UPS or FedEx
√ Step 2: Collect your sample and ship it back using the provided prepaid package
√ Step 3: RT-PCR Analysis of your sample (s) in our High-Complexity CLIA / CAP Certified Lab, FDA & EUA-Approved
√ Step 4: Receive your results online on same day or 24hrs via email, or patient portal (Your choice)
√ Step 5: Official Lab Report (s) provided
Self-Collected Saliva Based Sample Kit
Self-Collected Saliva Based Sample Kit is for RT-PCR Lab Test. Kit includes
Self-Collected Nasal Swab Test Kit
Our methodology we utilize to test for the SARS-CoV-2 virus is a state-of-the-Art RT-PCR testing process developed by experts in the field. The methodology is extremely sensitive, and it is listed as one of the most sensitive and specific SARS-CoV-2 test method out of more than 100 tests validated by the FDA (FDA: SARS-CoV-2 Reference Panel Comparative Data, 12/2020)
The assay is a multiplex rRT-PCR assay consisting of one reaction with primers and probes for the viral targets (Orf1ab, N and E genes) and internal control in one tube thus with increased assay throughput and ease of use and other advantages as a multiplex assay.
The Orf1ab, N, and E genes of the SARS-CoV-2 genome are targeted in the rRT-PCR assay. Primers and TaqMan probes designed for conserved regions of the SARS- CoV-2 virus genome allow specific amplification and detection of the viral RNA from all strains of SARS-CoV-2 from respiratory specimens. The Human RNase P gene is used as Internal control to monitor viral RNA extraction efficiency and assess amplifiable RNA in the samples to be tested.
High Throughput & Ease of Use
Orf1ab, N and E genes
93 samples (96-well plate) or 381 samples (384-well plate) per run
Ease of Use
One sample in one qPCR reaction well (1 assay mix/per sample)
KONE MOLECULAR LABS™ strive on excellence. Our work is performed based on the latest Science, and Technology. Our expert team has a collective brain power of over 80 years; Needless to say, our staff come from a diverse range of backgrounds, experience, and a plethora of educational interests.
Interested in a career with Kone Molecular Labs™? Our Career informational page is coming soon. CONTACT US if you wish to express your desire to work with us.
At KONE MOLECULAR LABS™, we believe our work is essential to community health. By offering close by access, affordable services, and science-based tests, we continue to build a framework that is poised to change as the world does. At KONE MOLECULAR LABS™, we are exploring, and creating new ideas on how to help more people stay safe, and healthy.
Posts • Papers • Publications
The Consortium for Mouse Cell Line Authentication was formed to validate Short Tandem Repeat (STR) markers for intraspecies identification of mouse cell lines. The STR profiling method is a multiplex polymerase chain reaction (PCR) assay comprised of primers targeting 19 mouse STR markers and two human STR markers (for interspecies contamination screening).
Overall, the interlaboratory study showed that the multiplex PCR method using 18 of the 19 mouse STR markers is capable of discriminating at the intraspecies level between mouse cell lines. Further studies are ongoing to refine the assay including (1) development of an allelic ladder for improving the accuracy of allele calling and (2) integration of stutter filters to identify true stutter.
Rapid Tests &
Test could measure patient immunity against multiple COVID-19 variants such as Omicron and Delta at once.
Biomedical engineers at Duke University have devised a test to quickly and easily assess how well a person’s neutralizing antibodies fight infection from multiple variants of COVID-19 such as Delta and the newly discovered Omicron variant.
This test could potentially tell doctors how protected a patient is from new variants and those currently circulating in a community or, conversely, which monoclonal antibodies to treat a COVID-19 patient. The test is described online in the journal Science Advances.
“In all of our tests, the results largely mimicked what we’ve been seeing in the literature,” said Jake Heggestad, a PhD student working in the Chilkoti lab. “And in this case, not finding anything new is a good sign, because it means our test is working just as well as the methods currently being used.”
December 3, 2021
Harvard Medical School
New research details how SARS-CoV-2 variants are evolving new ways to evade antibodies, vaccines.
In an effort to predict the future evolutionary maneuvers of SARS-CoV-2, a research team led by investigators at Harvard Medical School (HMS) has identified several likely mutations that would allow the virus to evade immune defenses, including natural immunity acquired through infection and developed from vaccination as well as antibody-based treatments.
The study, published in Science as an accelerated publication for immediate release, was designed to gauge how SARS-CoV-2 might evolve as it continues to adapt to its human hosts and in doing so to help public health officials and scientists prepare for future mutations.
Indeed, as the research was nearing publication, a new variant of concern, dubbed Omicron, entered the scene and was subsequently found to contain several of the antibody-evading mutations the researchers predicted in the newly published paper. As of December 1, omicron has been identified in 25 countries in Africa, Asia, Australia, Europe, and North and South America, a list that is growing daily.
The Blood-Brain Barrier and SARS-CoV-2
It is unclear whether severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019, can enter the brain. Severe acute respiratory syndrome coronavirus 2 binds to cells via the S1 subunit of its spike protein. We show that intravenously injected radioiodinated S1 (I-S1) readily crossed the blood–brain barrier in male mice, was taken up by brain regions and entered the parenchymal brain space. I-S1 was also taken up by the lung, spleen, kidney and liver. Intranasally administered I-S1 also entered the brain, although at levels roughly ten times lower than after intravenous administration.
APOE genotype and sex did not affect whole-brain I-S1 uptake but had variable effects on uptake by the olfactory bulb, liver, spleen and kidney. I-S1 uptake in the hippocampus and olfactory bulb was reduced by lipopolysaccharide-induced inflammation. Mechanistic studies indicated that I-S1 crosses the blood–brain barrier by adsorptive transcytosis and that murine angiotensin-converting enzyme 2 is involved in brain and lung uptake, but not in kidney, liver or spleen uptake.